Altimmune nears a key MASH trial readout, with strong market potential and new liver and alcohol studies supporting growth.

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Altimmune, Inc. (NASDAQ:ALT) was one of ...

GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and ...

Altimmune stock rose on Tuesday without news, possibly due to high short interest. Its new trial for Alcohol Use Disorder and ...

Altimmune is developing an anti-obesity drug, Pemvidutide, that shows promising results in targeting fat mass and promoting weight loss. The obesity treatment market is expected to grow ...

Altimmune, Inc. announced new analyses at the EASL Congress in Amsterdam, showcasing the MASH Resolution Index (MASHResInd) algorithm, developed by Dr. Rohit Loomba, to predict resolution in ...

GAITHERSBURG, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2025 ...

Altimmune Inc. ALT shares rallied more than 40% in the extended session Thursday after the clinical-stage biopharma company said 391 people enrolled in a trial of its obesity drug pemvidutide lost ...

Dec 5 (Reuters) - Weight-loss drug developer Altimmune (ALT.O), opens new tab is open to deals and collaborations with large drugmakers as it actively looks for partners to launch and develop its ...

March 13 (Reuters) - Altimmune (ALT.O), opens new tab said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol ...

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's ...